SCHEMBL5151396

SCHEMBL5151396

CCOc1ccc(-c2cccc(C(C)=O)c2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 1/20 0.60
▸ RXRB P28702 1/20 0.60
▸ KMT2A Q03164 4/20 0.55
▸ SMN1; SMN2 Q16637 3/20 0.55
▸ MEN1 O00255 3/20 0.55
▸ LMNA P02545 4/20 0.54
▸ NPC1 O15118 2/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ RAB9A P51151 1/20 0.54
▸ GAA P10253 1/20 0.54
▸ MAPT P10636 1/20 0.52
▸ HPGD P15428 1/20 0.52
▸ TSHR P16473 1/20 0.52
▸ TP53 P04637 1/20 0.51
▸ PKM P14618 1/20 0.51
▸ NFKB1 P19838 1/20 0.51
▸ NFKB2 Q00653 1/20 0.51
▸ RELA Q04206 1/20 0.51
▸ MRGPRX4 Q96LA9 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5154475 0.88 KMT2A (0.54) KMT2AMEN1LMNAALDH1A1RAB9A
SCHEMBL15183798 0.85 MEN1 (0.62) RXRARXRBKMT2ASMN1; SMN2MEN1
SCHEMBL18311606 0.84 LMNA (0.59) RXRARXRBSMN1; SMN2LMNANPC1
SCHEMBL9149730 0.83 L3MBTL1 (0.63) KMT2ASMN1; SMN2MEN1LMNANPC1
SCHEMBL8479394 0.82 HPGD (0.64) KMT2ASMN1; SMN2MEN1LMNANPC1
SCHEMBL307233 0.82 KMT2A (0.75) KMT2ASMN1; SMN2MEN1LMNANPC1
SCHEMBL2586835 0.81 KMO (0.59) KMT2ASMN1; SMN2MEN1LMNAALDH1A1
SCHEMBL23289051 0.81 HPGD (0.62) KMT2ASMN1; SMN2MEN1LMNANPC1
SCHEMBL30913837 0.81 HPGD (0.62) KMT2ASMN1; SMN2MEN1LMNANPC1
SCHEMBL16994145 0.80 RAB9A (0.56) KMT2ASMN1; SMN2MEN1LMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070060573-A1 Acyltryptophanols BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060573-A1 Acyltryptophanols FSHR, NPY1R, NPY2R RXRA 1256/4885RXRB 1669/4885KMT2A 916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback